HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Schachter, S. C. Search for Related Content PubMed PubMed Citation Articles by Schachter, S. C.

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

Drug-mediated antiepileptogenesis in humans

From the Department of Neurology, Harvard Medical School, Boston, MA.

Address correspondence and reprint requests to Dr. Steven C. Schachter, Department of Neurology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, K-478, Boston, MA 02215; e-mail: sschacht{at}caregroup.harvard.edu

The goal of pharmacologic therapy for patients with epilepsy is to suppress seizures without side effects. There is growing interest in developing antiepileptogenic drugs capable of preventing the onset of seizures in patients at high risk and inducing a permanent remission of seizures in patients with epilepsy, i.e., a cure. Whether any anticonvulsant drugs in current use have antiepileptogenic properties is the subject of this overview.